Results 11 to 20 of about 549,379 (280)

Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study

Radiation Oncology, 2022
Abstract Background To retrospectively analyze the efficacy and safety of concurrent chemoradiotherapy (CCRT) plus recombinant human endostatin (Endostar, CCRT + E) versus CCRT alone in locally advanced nasopharyngeal carcinoma (LANPC).
Yuanxiu Yin, Ziyan Zhou, Zhiru Li, Mingjun Shen, Yating Qin, Chaolin Yang, Rensheng Wang, Min Kang   +7 more
openaire   +4 more sources

Survival of Patients With Cervical Cancer Treated With Definitive Radiotherapy or Concurrent Chemoradiotherapy According to Histological Subtype: A Systematic Review and Meta-Analysis

Frontiers in Medicine, 2022
BackgroundCervical cancer is a leading cause of morbidity and mortality for women worldwide. Different histopathological cervical cancer subtypes (i.e., adenocarcinoma/adenosquamous carcinoma, and squamous cell carcinoma) are all treated similarly with ...
Guorong Yao, Jian Qiu, Fengjia Zhu, Xiaoxie Wang   +3 more
doaj   +2 more sources

Predictive value of lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-lymphocyte ratio (NLR) in patients with oesophageal cancer undergoing concurrent chemoradiotherapy

BMC Cancer, 2019
Background and objectives The survival rate of patients with advanced oesophageal cancer is very low and can vary significantly, even among patients with the same TNM stage. It is important to look for indicators that are economical and readily available
Ke-Jie Li, Xiao-Fang Xia, Meng Su, Hui Zhang, Wen-Hao Chen, Chang-Lin Zou   +5 more
doaj   +2 more sources

Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial

Nature Communications, 2023
In this multicenter, single-arm phase 2 trial (ChiCTR1900024428), patients with locally advanced gastric/gastroesophageal junction cancers receive one cycle of sintilimab (anti-PD1) and chemotherapy (S-1 and nab-paclitaxel), followed by 5 weeks of ...
Jia Wei, Xiaofeng Lu, Qin Liu, Yao Fu, Song Liu, Yang Zhao, Jiawei Zhou, Hui Chen, Meng Wang, Lin Li, Ju Yang, Fangcen Liu, Li-ming Zheng, H. Yin, Yang Yang, Chong Zhou, P. Zeng, Xiaoyu Zhou, N. Ding, Shiqing Chen, Xiaochen Zhao, Jing Yan, Xiangshan Fan, W. Guan, Baorui Liu   +24 more
semanticscholar   +1 more source

Effects of selenium supplementation on concurrent chemoradiotherapy in patients with cervical cancer: A randomized, double-blind, placebo-parallel controlled phase II clinical trial

Frontiers in Nutrition, 2023
Objective Selenium (Se) is an essential trace element and may affect cervical cancer occurrence and progression. The association between selenium supplementation and acute toxic reactions and clinical outcomes in patients with locally advanced cervical ...
Meijie Yang, B. Pei, Q. Hu, Xiao-ying Li, Xiping Fang, Xueming Huang, Zun-ming Yang, Jiaquan Chen, Du He, Guo-gen Sun, Peng Lv, Li Wang, Zixiong Zhang, L. Lai, Chuying Huang   +14 more
semanticscholar   +1 more source

Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2022
Importance Concurrent chemoradiotherapy has been the standard treatment for stage II nasopharyngeal carcinoma (NPC) based on data using 2-dimensional conventional radiotherapy.
L. Tang, R. Guo, Ning Zhang, Bin Deng, Lei Chen, Zhi-Bin Cheng, Jing Huang, Wei‐han Hu, S. Huang, Wei-Jun Luo, Jin-Hui Liang, Yu-ming Zheng, Fan Zhang, Y. Mao, Wen-Fei Li, G. Zhou, Xu Liu, Yupei Chen, Cheng Xu, Li Lin, Qing Liu, Xiao-jing Du, Yuan Zhang, Ying Sun, Jun Ma   +24 more
semanticscholar   +1 more source

Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

JAMA Oncology, 2022
This multicenter, open-label randomized clinical trial conducted in China compares the efficacy and safety of adjuvant capecitabine with concurrent chemoradiotherapy vs concurrent chemoradiotherapy alone for treatment of patients with locoregionally ...
J. Miao, Lin Wang, S. Tan, Jin-Gao Li, J. Yi, E. Ong, L. Y. Tan, Ye Zhang, X. Gong, Qiu-Yan Chen, Yan-Qun Xiang, Ming-Yuan Chen, Ying Guo, X. Lv, W. Xia, Linquan Tang, Xiaowu Deng, Xiang Guo, F. Han, H. Mai, M. Chua, Chong Zhao   +21 more
semanticscholar   +1 more source

The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction

Nature Communications, 2022
The synergistic effect of neoadjuvant immunotherapy and chemoradiotherapy in gastric adenocarcinoma is unclear. This phase II trial (NCT03631615) investigated this neoadjuvant combination in locally advanced adenocarcinoma of stomach or gastroesophageal ...
Zhaoqing Tang, Yan Wang, Dan Liu, Xuefei Wang, Chen Xu, Yiyi Yu, Yuehong Cui, Cheng Tang, Qian Li, Jing Sun, Qian Zhang, Yuan Ji, Guifen Ma, Haojie Li, Zhenbin Shen, K. Shen, Rongrong Zheng, Z. Hou, Tianshu Liu, Jiping Wang, Yihong Sun   +20 more
semanticscholar   +1 more source

A phase III multicenter randomized clinical trial of 60 Gy vs 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma.

Clinical Cancer Research, 2022
PURPOSE In this multicenter, phase 3 trial, the efficacy and safety of 60 Gy and 50 Gy doses delivered with modern radiation technology for definitive concurrent chemoradiation (CCRT) in patients with inoperable esophageal squamous cell carcinoma (ESCC ...
Yu-jin Xu, Baiqiang Dong, Wei-Guo Zhu, Jiancheng Li, R. Huang, Zongwen Sun, Xinmei Yang, Liping Liu, Han He, Z. Liao, Ni Guan, Y. Kong, Wanwei Wang, Jian-xiang Chen, Huijuan He, G. Qiu, M. Zeng, J. Pu, Wangyuan Hu, Y. Bao, Zhi-gang Liu, Jun Ma, Hao Jiang, Xianghui Du, Jin Hu, T. Zhuang, Jiong Cai, Jin Huang, H. Tao, Yuan-yuan Liu, Xiaodong Liang, Juying Zhou, G. Tao, Xiao Zheng, Ming Chen   +34 more
semanticscholar   +1 more source

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer

Thoracic Cancer, 2022
Durvalumab consolidation is associated with improved survival following concurrent chemoradiotherapy (CCRT) in patients with stage III non‐small cell lung cancer (NSCLC). Given the heterogeneity of stage III NSCLC patients, in this study we evaluated the
Yiqing Huang, Joseph J. Zhao, Y. Soon, Alvin S. C. Wong, F. Aminkeng, Yvonne L. E. Ang, Y. Asokumaran, J. Low, Matilda Lee, J. Choo, G. Chan, Adrian Kee, S. Tay, B. Goh, R. Soo   +14 more
semanticscholar   +1 more source